Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244609 | 1.00 | ALDH1A1 (0.37) | ALDH1A1PTGS2PTGS1 | |
| SCHEMBL989882 | 1.00 | ALDH1A1 (0.37) | ALDH1A1PTGS2PTGS1 | |
| Ethylene Glycol SCHEMBL11037616 | 0.92 | PTGS2 (0.36) | ALDH1A1PTGS2PTGS1 | |
| SCHEMBL3982028 | 0.85 | PTGS2 (0.33) | PTGS2PTGS1 | |
| SCHEMBL11060532 | 0.81 | — | — | |
| SCHEMBL3293937 | 0.81 | — | — | |
| SCHEMBL23370731 | 0.77 | ALDH1A1 (0.34) | ALDH1A1PTGS2PTGS1 | |
| SCHEMBL11063062 | 0.77 | LMNA (0.35) | ALDH1A1PTGS2 | |
| SCHEMBL12374845 | 0.77 | PTGS2 (0.38) | ALDH1A1PTGS2PTGS1 | |
| SCHEMBL11056580 | 0.77 | PTGS2 (0.35) | ALDH1A1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121665-B1 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-22 | — | — | EP | disclosed |
| EP-2121664-B1 | DINITRATE DERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8367711-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8293777-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME, CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-09-20 | — | — | US | disclosed |
| US-8252825-B2 | Angiotensin II receptor antagonists | NICOX (IT) | 2012-08-28 | — | — | US | disclosed |
| US-8207208-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2373630-A1 | NITROOXY DERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2313417-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Nicox S.A. (FR) | 2011-04-27 | — | — | EP | disclosed |
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2011-03-31 | — | — | US | disclosed |
| US-20100144810-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-06-10 | — | — | US | disclosed |
| WO-2010015447-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2010-02-11 | — | — | WO | disclosed |
| WO-2009150007-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009140111-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009070241-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20080242722-A1 | Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events | DUFRESNE CLAUDE | 2008-10-02 | — | — | US | disclosed |
| US-20080194660-A1 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| WO-2008076247-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1603933-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004098538-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, AGT | ALDH1A1 2089/4885PTGS2 428/4885PTGS1 656/4885 |
| US-20080242722-A1 | Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events | PTGS2, PTGS1, PTGES2 | ALDH1A1 372/4885PTGS2 1/4885PTGS1 2/4885 |
| US-20080194660-A1 | Angiotensin II receptor antagonists | AGTR1, AGTR2, REN | ALDH1A1 3538/4885PTGS2 1456/4885PTGS1 1479/4885 |
| US-20120238608-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | ALDH1A1 2760/4885PTGS2 1153/4885PTGS1 1114/4885 |
| US-20100144810-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | ALDH1A1 2024/4885PTGS2 861/4885PTGS1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.